Zydus Lifesciences Ltd
In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20.
Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe
- Market Cap ₹ 96,402 Cr.
- Current Price ₹ 958
- High / Low ₹ 1,324 / 681
- Stock P/E 22.2
- Book Value ₹ 178
- Dividend Yield 0.31 %
- ROCE 22.9 %
- ROE 23.4 %
- Face Value ₹ 1.00
Pros
- Company has delivered good profit growth of 19.5% CAGR over last 5 years
- Company has been maintaining a healthy dividend payout of 26.1%
Cons
- Company has high debtors of 160 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Part of BSE 250 LargeMidCap Index Nifty LargeMidcap 250 Nifty 500 Multicap 50:25:25 Nifty100 ESG BSE 500
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
3,527 | 4,042 | 5,284 | 7,032 | 3,231 | 5,810 | 6,037 | 6,347 | 7,780 | 7,837 | 8,732 | 10,819 | 12,484 | |
2,820 | 3,232 | 3,750 | 4,454 | 2,909 | 4,164 | 4,400 | 4,916 | 5,468 | 5,916 | 6,277 | 6,760 | 6,901 | |
Operating Profit | 708 | 810 | 1,535 | 2,578 | 322 | 1,646 | 1,637 | 1,432 | 2,312 | 1,921 | 2,454 | 4,059 | 5,583 |
OPM % | 20% | 20% | 29% | 37% | 10% | 28% | 27% | 23% | 30% | 25% | 28% | 38% | 45% |
51 | 305 | 184 | 174 | 582 | 208 | 598 | 848 | -102 | -144 | 345 | 1,076 | 893 | |
Interest | 111 | 42 | 43 | 26 | 11 | 64 | 90 | 234 | 71 | 135 | 278 | 391 | 421 |
Depreciation | 117 | 127 | 212 | 221 | 251 | 293 | 358 | 429 | 451 | 479 | 489 | 504 | 523 |
Profit before tax | 531 | 946 | 1,465 | 2,504 | 642 | 1,497 | 1,787 | 1,617 | 1,688 | 1,164 | 2,032 | 4,240 | 5,532 |
Tax % | 6% | 4% | 13% | 19% | -3% | 27% | 17% | 13% | 13% | 26% | 25% | 19% | |
499 | 904 | 1,271 | 2,038 | 662 | 1,091 | 1,486 | 1,413 | 1,476 | 858 | 1,529 | 3,442 | 4,346 | |
EPS in Rs | 4.87 | 8.83 | 12.42 | 19.90 | 6.47 | 10.66 | 14.51 | 13.80 | 14.42 | 8.38 | 15.11 | 34.20 | 43.16 |
Dividend Payout % | 31% | 20% | 19% | 16% | 50% | 33% | 24% | 25% | 24% | 30% | 40% | 9% |
Compounded Sales Growth | |
---|---|
10 Years: | 10% |
5 Years: | 12% |
3 Years: | 12% |
TTM: | 29% |
Compounded Profit Growth | |
---|---|
10 Years: | 14% |
5 Years: | 19% |
3 Years: | 28% |
TTM: | 75% |
Stock Price CAGR | |
---|---|
10 Years: | 12% |
5 Years: | 30% |
3 Years: | 28% |
1 Year: | 39% |
Return on Equity | |
---|---|
10 Years: | 17% |
5 Years: | 15% |
3 Years: | 15% |
Last Year: | 23% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 101 | 101 | 101 |
Reserves | 2,809 | 3,528 | 4,423 | 6,174 | 6,516 | 7,643 | 8,467 | 11,158 | 12,642 | 13,138 | 13,538 | 15,616 | 17,797 |
1,786 | 1,586 | 1,450 | 1,223 | 2,940 | 2,872 | 3,583 | 3,695 | 3,920 | 2,665 | 4,825 | 6,178 | 4,780 | |
855 | 1,027 | 1,362 | 1,424 | 1,489 | 1,546 | 1,519 | 1,597 | 1,799 | 1,835 | 2,099 | 2,190 | 2,757 | |
Total Liabilities | 5,552 | 6,243 | 7,337 | 8,923 | 11,047 | 12,164 | 13,671 | 16,552 | 18,464 | 17,740 | 20,564 | 24,085 | 25,435 |
1,497 | 1,564 | 1,768 | 2,155 | 2,352 | 2,680 | 3,932 | 4,109 | 4,112 | 4,336 | 4,184 | 4,369 | 4,270 | |
CWIP | 464 | 531 | 367 | 297 | 678 | 659 | 675 | 553 | 570 | 384 | 739 | 634 | 978 |
Investments | 1,280 | 1,558 | 2,209 | 2,318 | 3,924 | 3,618 | 4,195 | 6,404 | 6,471 | 5,118 | 4,879 | 7,283 | 7,305 |
2,311 | 2,591 | 2,993 | 4,154 | 4,093 | 5,206 | 4,868 | 5,486 | 7,310 | 7,902 | 10,761 | 11,798 | 12,883 | |
Total Assets | 5,552 | 6,243 | 7,337 | 8,923 | 11,047 | 12,164 | 13,671 | 16,552 | 18,464 | 17,740 | 20,564 | 24,085 | 25,435 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
445 | 878 | 1,084 | 1,954 | 867 | 288 | 581 | 1,181 | 2,227 | 1,272 | 1,078 | 1,999 | |
-709 | -408 | -577 | -1,016 | -2,480 | 28 | -713 | 55 | -2,714 | 586 | -1,959 | -1,831 | |
250 | -446 | -387 | -923 | 1,366 | -149 | 65 | -967 | 255 | -1,710 | 827 | -301 | |
Net Cash Flow | -14 | 25 | 120 | 14 | -247 | 167 | -67 | 268 | -231 | 149 | -54 | -132 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 71 | 65 | 73 | 89 | 105 | 79 | 128 | 141 | 89 | 106 | 147 | 160 |
Inventory Days | 169 | 171 | 178 | 127 | 338 | 284 | 288 | 261 | 276 | 245 | 205 | 195 |
Days Payable | 104 | 119 | 148 | 174 | 361 | 173 | 137 | 161 | 175 | 135 | 120 | 129 |
Cash Conversion Cycle | 136 | 117 | 102 | 42 | 82 | 190 | 279 | 241 | 191 | 216 | 232 | 227 |
Working Capital Days | 72 | 61 | 53 | 70 | 74 | 118 | 161 | 138 | 205 | 225 | 208 | 188 |
ROCE % | 15% | 20% | 27% | 38% | 8% | 15% | 16% | 14% | 12% | 10% | 14% | 23% |
Documents
Announcements
- Closure of Trading Window 2h
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
19 Dec - Zydus receives USFDA approval for Lidocaine and Prilocaine Cream.
-
Update On Disinvestment Of Equity Stake Of Mylab Discovery Solutions Private Limited
17 Dec - Zydus Lifesciences disinvests 6.5% stake in Mylab.
-
Announcement under Regulation 30 (LODR)-Diversification / Disinvestment
16 Dec - Disinvestment of 6.5% stake in Mylab for Rs. 106 Crores.
-
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
4 Dec - Intimation of loss and duplicate share certificates.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
Concalls
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT REC
-
Aug 2024TranscriptNotesPPT REC
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Sep 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Sep 2021TranscriptPPT
-
Aug 2021Transcript PPT
-
May 2021TranscriptPPT
-
Feb 2021TranscriptPPT
-
Jan 2021TranscriptNotesPPT
-
Oct 2020TranscriptPPT
-
Aug 2020TranscriptNotesPPT
-
Aug 2020Transcript PPT
-
Jun 2020TranscriptPPT
-
Mar 2020TranscriptPPT
-
Feb 2020TranscriptNotesPPT
-
Feb 2020TranscriptNotesPPT
-
Nov 2019TranscriptPPT
-
Jul 2019TranscriptPPT
-
Jun 2019Transcript PPT
-
Jan 2019TranscriptNotesPPT
-
Jan 2019TranscriptNotesPPT
-
Jun 2018TranscriptNotesPPT
-
May 2018TranscriptPPT
-
Nov 2017TranscriptNotesPPT
-
Sep 2017TranscriptNotesPPT
-
Jun 2017Transcript PPT
-
Mar 2017TranscriptNotesPPT
-
Feb 2017TranscriptNotesPPT
-
Jan 2017TranscriptPPT
-
Nov 2016Transcript PPT
-
May 2016Transcript PPT
Business Segments